Location History:
- Issaquah, WA (US) (2013)
- Westlake Village, CA (US) (2015 - 2016)
- Newbury, CA (US) (2017)
- Newbury Park, CA (US) (2016 - 2019)
- Thousand Oaks, CA (US) (2019 - 2023)
- South San Francisco, CA (US) (2023)
- Daly City, CA (US) (2016 - 2024)
Company Filing History:
34 out of 1,975 
2 out of 52 
1 out of 832,880 Years Active: 2013-2024
Title: Gunasekaran Kannan: A Pioneer in T-Cell Regulation
Introduction
Gunasekaran Kannan, based in Daly City, California, is an accomplished inventor with a significant contribution to the field of immunology. With a remarkable portfolio of 37 patents, Kannan's work primarily focuses on the development of innovative therapies that enhance the regulation of T regulatory cells, vital for maintaining immune system balance.
Latest Patents
Among his latest patents, Kannan presents groundbreaking inventions related to Interleukin-2 muteins. These inventions include IL-2 muteins and IL-2 mutein Fc-fusion molecules that are designed to preferentially expand and activate T regulatory cells, enabling large-scale production capabilities. His research also delves into variant human IgG1 Fc molecules that maintain high stability and reduced effector function, even in the absence of glycosylation at N297. Furthermore, Kannan has developed linker peptides that are glycosylated within mammalian cells, along with methods for producing and utilizing these innovative compositions.
Career Highlights
Kannan has worked with leading biopharmaceutical companies, including Amgen Inc. and Denali Therapeutics Inc., where he has been instrumental in advancing therapeutic solutions for various diseases through his patent portfolio. His extensive experience has positioned him as a key figure in the field of biotechnology.
Collaborations
Throughout his career, Kannan has collaborated with notable colleagues, including Zhulun Wang and Kenneth William Walker. These collaborations have allowed for the cross-pollination of ideas and innovation, driving progress in their shared field of research.
Conclusion
Gunasekaran Kannan's contributions, particularly in the realm of T regulatory cell expansion, have the potential to greatly impact immunotherapy and enhance therapeutic outcomes for patients. His patents reflect a deep commitment to innovation and the advancement of medical science, solidifying his reputation as a leader in his area of expertise.